Ikerian AG Closes Series A Extension Financing

Ikerian AG, the parent company of RetinAI U.S. Inc., has successfully closed its Series A Extension financing, bringing in a total of USD 6.18M (CHF 5.65M) from new and existing investors. The lead investor for this final close was the Corporate Venture Capital arm of Topcon Healthcare, Inc. This funding will support the continued development and commercial rollout of RetinAI Discovery® in the ophthalmology and optometry market, as well as Ikerian's expansion into new therapeutic areas such as neurodegenerative disorders, vascular conditions, and rare diseases. The company has rebranded as Ikerian AG to spearhead development beyond ophthalmology, with RetinAI U.S. Inc. focusing on the ophthalmology market. Dr. Carlos Ciller, Chairman and CEO of Ikerian, expressed his excitement about the financing, highlighting the importance of AI technology in revolutionizing workflows for clinical and pharmaceutical research to enhance patient care. RetinAI has achieved significant milestones, including strategic collaborations with Retina Consultants of America and major pharma companies like Boehringer Ingelheim, Janssen, and Novartis. The company's RetinAI Discovery® platform has received FDA 510(k) clearance for clinical use and integration into U.S.-based clinics, marking a significant achievement in the AI-driven healthcare space. The Series A Extension financing brings the total equity raised to USD 11.66M (CHF 10.66M), paving the way for further growth and development opportunities. Dr. Ciller emphasized the company's commitment to leveraging the 'eye as a window to the body' to advance healthcare in systemic and chronic diseases, underscoring Ikerian's role in improving healthcare worldwide.